-
Rothschild's bigger war chest EPS watch At least 11 profitable biotechs and pharmas reported earnings last week. Specialty pharma Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) added $1.8 billion in …
Published on 3/5/2012
-
Ebb & Flow Key to healthcare Healthcare venture investor KeyView Partners is ready to make its first investment despite not having a formal fund. KeyView is aiming to tap an established network of institutions and …
Published on 3/5/2012
-
Ebb & Flow AD to Orphan The expense and difficulty of clinical development in Alzheimer's disease has discouraged NeuroPhage Pharmaceuticals Inc. from pursuing the indication as a full blown program. However, the …
Published on 3/5/2012
-
Two public Asian biotechs, Japan's NanoCarrier and Korea's CrystalGenomics, are using venture debt-style offerings to make it through the development desert.
Published on 3/5/2012
-
Ebb & Flow Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) jumped $1.63 (71%) to $3.94 on Tuesday, while partner pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.27 (13%) to $2.42, after the U.K. and six …
Published on 3/5/2012
-
Ebb & Flow Rothschild's bigger war chest Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Edmond de Rothschild Investment Partners has determined that bigger is better and thus is out raising…
Published on 3/5/2012
-
Ebb & Flow Bridge to acquisition First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is betting that its more selective gamma secretase modulator will not …
Published on 2/27/2012
-
Ebb & Flow Banker tracks RBS Group (LSE:RBS; NYSE:RBS) promoted Stuart Dean to head of healthcare in the corporate and institutional banking team. He was director of origination for the structured finance group. …
Published on 2/27/2012
-
Ebb & Flow Caxton team to Valence The founders of Caxton Advantage Venture Partners are leaving to start a new firm, Valence Life Sciences. Rachel Leheny and Eric Roberts started Caxton Advantage in 2006 as part of…
Published on 2/27/2012
-
Cashing in on Qnexa Money Raised in 2012 Last week, the biotech industry raised $194 million, bringing to $5.6 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 …
Published on 2/27/2012
-
Cashing in on Qnexa Earnings on deck At least nine biotechs and pharmas are slated to report earnings this week. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) are expected to …
Published on 2/27/2012
-
Cashing in on Qnexa EPS watch At least nine profitable biotechs and pharmas reported earnings last week. Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) added nearly $500 million in market value after reporting …
Published on 2/27/2012
-
Ebb & Flow Cashing in on Qnexa Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Despite the ups and downs of Vivus Inc. (NASDAQ:VVUS) over the past few years, some investments in the obesity …
Published on 2/27/2012
-
Ebb & Flow Regulatory milestones Chelsea Therapeutics International Inc. (NASDAQ:CHTP) was up $1.47 (61%) to $3.88 on Friday after FDA's Cardiovascular and Renal Drugs Advisory Committee voted on Thursday to …
Published on 2/27/2012
-
Follow-ons are thriving, the question is for how long? While biotech stocks are already at the top of the typical run that fuels financings, bankers see enough investor appetite to keep the window open.
Published on 2/20/2012
-
Bon appétit Money Raised in 2012 Last week, the biotech industry raised $938 million, bringing to $5.4 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 billion in …
Published on 2/20/2012
-
Bon appétit Earnings on deck At least seven profitable biotechs and pharmas are slated to report earnings this week. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), which markets cancer drug Nexavar sorafenib with Bayer AG…
Published on 2/20/2012
-
Bon appétit EPS watch At least six biotechs and pharmas reported earnings last week. Acorda Therapeutics Inc. (NASDAQ:ACOR), Charles River Laboratories International Inc. (NYSE:CRL) and Teva Pharmaceutical …
Published on 2/20/2012
-
Open wide, for now No exit? A surge in biotech stock prices followed by strong follow-on activity often presaged an IPO window. But this hasn't been the case since the economic crisis of 2008-09. In fact, biotech …
Published on 2/20/2012
-
Open wide, for now Peaks & troughs Run-ups by the BioCentury 100 and NASDAQ Biotechnology indices have typically lost steam following 25%-plus gains (see BioCentury, April 5, 2010). Since Aug. 8, 2011, the BC100 and…
Published on 2/20/2012
-
Ebb & Flow Angel to public Bioprinting play Organovo Holdings Inc. (OTCQB:ONVO) jumped directly from angel investment to the public markets to avoid a large, dilutive VC round. The biotech, which was formed in 2007…
Published on 2/20/2012
-
Ebb & Flow Form 10 for ADMA Investors in ADMA Biologics Inc.'s private placement don't mind holding a relatively illiquid stock, as the syndicate is expecting a Phase III data event before the company's cash runs …
Published on 2/20/2012
-
Ebb & Flow Bon appétit Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Strong demand for the first European biotech IPO of the year may signal an increased appetite for risk from European …
Published on 2/20/2012
-
Ebb & Flow Regulatory milestones BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) gained $0.21 (27%) to $0.97 on Wednesday after FDA approved an NDA from partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) for Bio-…
Published on 2/20/2012
-
Ebb & Flow Regulatory milestones Amgen Inc. (NASDAQ:AMGN) was off $1.92 to $67.36 last week after FDA's Oncologic Drugs Advisory Committee voted 12-1 on Wednesday that Xgeva denosumab does not have a favorable …
Published on 2/13/2012